Baxter announced Oct. 31 that it has restarted its North Cove, N.C. facility's highest-throughput IV solutions manufacturing line, which normally accounts for nearly 25% of the site's total production and approximately 50% of its one-liter IV solutions — the most commonly used size by hospitals and clinics. The earliest new products could begin shipment is late November, Baxter said. The company is continuing to assess and repair equipment at the facility and is working with the Food and Drug Administration to resume operation in phases. Baxter said it does not have a timeline on when production at the facility will be restored to pre-Hurricane Helene levels. 

Related News Articles

Headline
Supplies of Mo-99/Tc-99M, which are medical radioisotopes used in procedures to diagnose and detect diseases including heart disease and cancer, are…
Headline
The AHA Oct. 28 issued a Special Bulletin to members informing them of the Food and Drug Administration's authorization extending the use date for certain…
Headline
The Centers for Disease Control and Prevention has issued a health advisory on the supply disruption of peritoneal dialysis and intravenous solutions due to…
Headline
Baxter announced that it is increasing the current U.S. allocation levels of its highest-demand IV fluids for direct customers from 40% to 60%, and for…
Headline
The Centers for Disease Control and Prevention has issued an advisory alerting health care providers, laboratory professionals and others in health care…